ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

BSX vs. ABT: Which Medical Stock Has More Upside Potential?

Zacks Investment Research

10:16 AM | Friday | May 29, 2026

news photo
Loading...

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Read full article redirect
10:16 AM | Friday | May 29, 2026

BSX vs. ABT: Which Medical Stock Has More Upside Potential?

Zacks Investment Research

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Read full article arrow
News Thumbnail
10:01 AM | Friday | May 29, 2026

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
10:31 AM | Thursday | May 28, 2026

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

Zacks Investment Research

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read full article arrow
News Thumbnail
9:53 AM | Wednesday | May 27, 2026

How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026

Zacks Investment Research

ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 27, 2026

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

PRNewsWire

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.

Read full article arrow
News Thumbnail
7:01 AM | Wednesday | May 27, 2026

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

PRNewsWire

Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | May 26, 2026

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

PRNewsWire

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago.

Read full article arrow
News Thumbnail
9:15 PM | Friday | May 22, 2026

The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech

Fool - Investing News

When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.

Read full article arrow
News Thumbnail
2:30 AM | Thursday | May 21, 2026

3 Stocks to Buy if You Think the Economy Is Heading for a Recession

Fool - Investing News

They have increased their payouts for a combined 171 years straight.

Read full article arrow
News Thumbnail
9:41 AM | Wednesday | May 20, 2026

Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum

Zacks Investment Research

ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.

Read full article arrow
News Thumbnail